Track market-moving stories before they get noisy

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Many on Wall Street argue that oil prices could remain elevated regardless of how the Iran conflict resolves, for several structural reasons. Global spare capacity is largely concentrated in a handful of OPEC+ nations. It has grown increasingly thin, meaning any disruption to supply chains, shipping lanes, or refining infrastructure takes longer to be absorbed and worked through the system. The Strait of Hormuz remains a critical path for roughly 20% of the global oil trade, and even a ceasefire or de-escalation wouldn’t instantly restore insurer confidence or normalize tanker routing, keeping freight and risk premiums largely baked into prices.

Years of underinvestment in upstream exploration and production mean the supply side can’t respond quickly to demand signals the way it once could. Add to that a weaker dollar environment, persistent demand from emerging markets, particularly India and China, and OPEC+’s demonstrated willingness to defend price floors through coordinated cuts, and the conditions for structurally higher oil exist well beyond the current hostilities in the Middle East. The bottom line for investors is that if they are underweight or don’t own any energy names, now’s the time to consider adding some to a portfolio. But after a massive rally that started when the conflict with Iran began in late February, it makes sense to look at the safest energy companies now.

We decided to screen our 24/7 Wall St. energy stock database, looking for companies that still deliver large and dependable dividends while remaining good investments on a valuation basis. While we remain positive on the mega-cap integrated giants, they have had spectacular runs and would be much better purchases after a solid price pullback.

Five companies that pay significant dividends and offer shareholders some of the best valuations currently are at the top of our strong buy list for investors. All still offer reasonable entry points, with outstanding upside potential to the posted Wall Street target prices. All five are also rated Buy at the top Wall Street firms we cover at 24/7 Wall St.

Why do we cover the safest high-yielding energy dividend stocks? Since 1926, dividends have accounted for approximately 32% of the S&P 500’s total return, while capital appreciation has accounted for 68%. Therefore, sustainable dividend income and the potential for capital appreciation are essential to total return expectations. A study by Hartford Funds, in collaboration with Ned Davis Research, found that dividend stocks delivered an annualized return of 9.18% over the past 50 years (1973 to 2023). Over the same timeline, this was more than double the annualized return for non-payers (3.95%).

Brookfield Renewable Partners This off-the-radar utility stock is an ideal choice now for growth and income investors, as well as those concerned with environmental issues. Brookfield Renewable Partners (NYSE: BEP | BEP Price Prediction) operates publicly traded platforms for renewable power and decarbonization solutions. Investors are paid a rich 4.41% dividend. Earnings rose 15% in Q1 2026 and 12% over the trailing twelve months. The company expects double-digit earnings growth to continue for at least the next five years. Since going public in 2011, it has raised its dividend by at least 5% every year and targets dividend growth of 5% to 9% going forward.

The company’s renewable power portfolio includes:

Hydroelectric Wind Utility-scale solar Distributed generation Storage facilities located across North America, South America, Europe, and the Asia-Pacific region Its operations are divided into six segments:

Hydroelectric, which is further categorized by geography (North America, Colombia, and Brazil) Wind Utility-scale solar Distributed energy and storage, including distributed generation Pumped storage Battery energy storage systems; sustainable solutions, encompassing agricultural renewable natural gas, carbon capture and storage, recycling, cogeneration, biomass, nuclear services, electrofuels, and power transformation Corporate The company’s total power portfolio comprises approximately 46,200 megawatts of installed capacity and a development pipeline of approximately 200,000 megawatts.

TD Securities has a Buy rating with a $39 target price.

Clearwater Energy This is another off-the-radar company that is safe and still bargain-priced, with a strong 4.42% dividend. Clearwater Energy (NYSE: CWEN) is a renewable energy company that invests in energy infrastructure, focuses on clean energy, and owns modern, sustainable, and long-term-contracted assets across North America. It is one of the largest renewable energy companies in the U.S., with a portfolio of wind, solar, and energy storage facilities across 27 states totaling approximately 12.7 gigawatts of gross capacity. Both share classes have risen more than 20% over the past 12 months. The data center boom has been a significant growth driver.

Clearwater Energy’s operating facilities include:

Carlsbad El Segundo GenConn Devon GenConn Middletown Marsh Landing Walnut Creek The company’s utility-scale solar projects include:

Agua Caliente Alpine Avenal Avra Valley Blythe Borrego Buckthorn Solar CVSR Daggett 2 Daggett 3 Desert Sunlight 250 Kansas South The company’s wind projects include Black Rock, Buffalo Bear, Cedro Hill, Crofton Bluffs, and Cedar Creek.

UBS has a Buy rating with a $45 target price.

Enbridge Enbridge owns and operates pipelines throughout Canada and the United States. This is an off-the-radar idea based in Canada, poised to break out to new highs soon, and pays a rich 6.94% dividend. Enbridge (NYSE: ENB) operates as an energy infrastructure company. Enbridge announced its 31st consecutive annual dividend increase in 2026, lifting the payout by another 3%, and has paid dividends for over 70 years. With roughly 98% of its annual earnings backed by long-term, fixed-rate contracts and regulated rate structures, the company stands out as one of the most defensive and reliable plays in the energy infrastructure sector.

The company operates through five segments:

Liquids Pipelines Gas Transmission and Midstream Gas Distribution and Storage Renewable Power Generation Energy Services The Liquids Pipelines segment operates pipelines and related terminals in Canada and the United States to transport various grades of crude oil and other liquid hydrocarbons.

The Gas Transmission and Midstream segment invests in natural gas pipelines and gathering and processing facilities in Canada and the United States. The Gas Distribution and Storage segment is involved in natural gas utility operations, serving residential, commercial, and industrial customers in Ontario, as well as in natural gas distribution and energy transportation activities in Quebec.

The Renewable Power Generation segment operates power-generating assets, including wind, solar, geothermal, and waste heat recovery facilities, as well as transmission assets, in North America and Europe. The Energy Services segment provides energy marketing services to refiners, producers, and other customers, as well as physical commodity marketing and logistical services in Canada and the United States.

Royal Bank of Canada has an Outperform rating and a $79 target price.

Energy Transfer Energy Transfer (NYSE: ET) is one of North America’s largest and most diversified midstream energy companies. This top master limited partnership is a safe option for investors seeking energy exposure and income, as the company pays a 6.67% distribution yield. It owns and operates one of the largest and most diversified portfolios of energy assets in the United States, with a strategic footprint across all major domestic production basins. As a midstream MLP, its revenue is largely fee-based and less sensitive to commodity price swings.

The company is a publicly traded limited partnership with core operations that include:

Complementary natural gas midstream, intrastate, and interstate transportation and storage assets Crude oil, natural gas liquids (NGL), and refined product transportation and terminalling assets NGL fractionation Various acquisition and marketing assets Following the acquisition of Enable Partners in December 2021, Energy Transfer owns and operates over 114,000 miles of pipelines and related assets in 41 states, spanning all major U.S. producing regions and markets. This solidifies its leadership position in the midstream sector.

Through its ownership of Energy Transfer Operating, formerly known as Energy Transfer Partners, the company also owns Lake Charles LNG; the general partner interests, the incentive distribution rights, and 28.5 million standard units of Sunoco (NYSE: SUN); and the public partner interests and 39.7 million standard units of USA Compression Partners (NYSE: USAC).

Stifel has a Buy rating on the shares, with a $25 target price.

Enterprise Products Partners This top midstream giant is an American midstream natural gas and crude oil pipeline company headquartered in Houston, Texas. Enterprise Products Partners (NYSE: EPD) is one of the most extensive publicly traded energy partnerships, and it pays a very reliable 5.84% dividend. The company’s debt-to-EBITDA ratio ranges from 3.1x to 3.4x, which is moderate for a midstream energy company, and its interest coverage ratio is 5x.

Enterprise Products Partners generates strong free cash flow, with an operating cash flow of approximately $8.8 billion, resulting in approximately $4.2 billion in free cash flow annually after deducting capital expenditures. Another significant benefit for shareholders is that most of the corporate debt is fixed-rate, thereby limiting the risk of rising interest rates.

It provides various midstream energy services, including:

Gathering Processing Transporting and storing natural gas, natural gas liquids (NGL), and fractionation Import and export terminalling Offshore production platform services The company has four reportable business segments:

Natural Gas Pipelines and Services NGL Pipelines and Services Petrochemical Services Crude Oil Pipelines and Services One reason many analysts like the stock might be its distribution coverage ratio. The company’s coverage ratio is well above 1x, making it relatively less risky among the MLPs.

Citigroup has a Buy rating with a $45 price objective.

Renewable energy stocks were supposed to be some of the losers under the second Trump administration. The president is famously not a fan of wind turbines or solar energy. Yet one diversified energy play is having an outstanding year.

Shares of Brookfield Renewable Partners (BEP +0.31%) have soared by 37.5% year to date through May. Here's a look at several reasons investors shouldn't overlook Brookfield Renewable Partners, but also one reason to be wary.

Image source: The Motley Fool.

Brookfield is diversified Brookfield Renewable's underlying business is one of the reasons the stock has performed well so far this year. The company continued its trend of growing funds from operations (FFO), with a 19% year-over-year increase in Q1. The financial measure, commonly used by real estate investment trusts (REITs), defines cash generated from underlying operations and has increased by 12% over the last year versus the prior period.

Connor Teskey, CEO of Brookfield Renewable and president of Brookfield Asset Management, summarized the company's recent success this way:

Growing energy demand is now occurring alongside a renewed focus on energy security. In an environment with strong demand for low-cost, quick-to-market, and increasingly locally sourced energy, we are well positioned to deliver sustainable, long-term cash flow growth for our investors.

Brookfield was poised to capitalize on the growing demand, thanks to its diversification across energy markets and technologies. While a little over half of its assets under management are in North America, the company also has meaningful energy assets in Europe, Latin America, and across the Asia-Pacific region.

Today's Change

(

0.31

%) $

0.11

Current Price

$

35.38

Power production assets are in demand as data centers increase global energy demand and the Strait of Hormuz conflict rattles oil markets. It highlights where Brookfield's expertise makes a difference. The company is a strong capital allocator, and management constantly works to identify its best opportunities. In that vein, Brookfield Renewable announced $3 billion in asset sales in Q1 alone as it recycles capital into projects it believes offer better returns.

BEP or BEPC? The equity is also unique. Brookfield Renewable offers partnership units, but investors can also purchase shares of Brookfield Renewable Corp. (BEPC +0.51%). BEP units and BEPC shares both represent the same underlying business and assets. The former is a limited partnership, while the latter is a corporation.

Owning shares in the partnership can lead to more complex tax paperwork, which turns off some investors. That helps explain the recent pricing deviation. Although they pay the same dividend amount per share/unit, their market prices diverged, resulting in different yields.

Data by YCharts.

The partnership units have been playing catch-up this year, resulting in the outsize return. Investors can choose which to buy based on personal situations and tax preparation concerns. But there is no doubt that the underlying business is strong, and Brookfield is a solid renewable energy dividend stock to own. Just don't expect the pace of returns to mirror what we've seen so far in 2026, as the partnership unit price has now closed the gap.

New breakthroughs in low-cost hydrogen extraction and growing clean energy demand position the sector for significant long-term market expansion

, /PRNewswire/ -- Market News Updates News Commentary - The Engineered Mineral Hydrogen sector is gaining momentum as the demand for cleaner and more cost-effective energy sources grows globally. Unlike traditional hydrogen production methods that heavily depend on natural gas or expensive electrolysis systems, Engineered Mineral Hydrogen harnesses natural chemical reactions between water and iron-rich rocks deep below the surface to generate hydrogen in a more sustainable way. Many companies are now exploring ultramafic rock formations and serpentinization processes as scalable energy solutions, especially in regions rich in nickel and iron reserves. Recent industry advancements, like new partnerships and trial projects in Newfoundland and North America, signify a shift from research to commercial deployment.  Active Companies mentioned in the article includes: First Atlantic Nickel Corp. (OTCQB: FANCF) (TSX-V: FAN), Total Energy Services Inc. (OTC: TOTZF) (TSX: TOT), Exxon Mobil Corporation (NYSE: XOM), Chevron Corporation (NYSE: CVX), Brookfield Renewable Partners L.P. (NYSE: BEP).

One attractive aspect for investors in this field is the potential cost-effectiveness. Experts believe that engineered or natural hydrogen could eventually become one of the most cost-efficient forms of clean hydrogen due to the earth's natural gas production capabilities, reducing the need for extensive industrial energy inputs. The global hydrogen market is expected to see significant growth, reaching approximately $66.5 billion by 2034 from $21.7 billion in 2026, driven by increasing industrial demand, transportation, AI-driven data centers, and energy storage applications. Simultaneously, the emerging natural and engineered hydrogen sector is projected to experience even faster growth, with market analyses suggesting that the natural hydrogen market could surge from about $158 million in 2025 to over $2.2 billion by 2032.

The excitement surrounding Engineered Mineral Hydrogen is fueled by rising concerns over energy security and growing interest in low-carbon industrial fuels. Companies are increasingly looking for reliable domestic energy sources to reduce dependence on imported fuels while supporting decarbonization efforts. Analysts predict a notable increase in drilling projects, pilot installations, and long-term contracts beyond 2026 as the sector develops. Although still in its early stages and carrying exploration risks similar to mining or oil exploration, many investors see it as a disruptive opportunity within the broader clean energy market landscape. If commercial-scale production proves successful, Engineered Mineral Hydrogen has the potential to play a crucial role in the global energy mix in the next decade.

Vema Hydrogen and First Atlantic Nickel & Cobalt Sign LOI to Develop Engineered Mineral Hydrogen at Pipestone XL Awaruite Project in Newfoundland 

Vema's Engineered Mineral Hydrogen could supply regional industry and seaborne export markets from the Pipestone XL Project in central Newfoundland. The Pipestone Ophiolite Complex spans 30 kilometers of ultramafic rock, and holds enough potential hydrogen to power industrial demand in Newfoundland for generations Vema Hydrogen ("Vema") today announced that it has entered into a non-binding Letter of Intent (the "LOI") with First Atlantic Nickel & Cobalt Corp (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) ("First Atlantic"), to jointly develop Engineered Mineral Hydrogen, or EMH, at the Pipestone XL project, a 30-kilometer ultramafic belt in central Newfoundland. Under the LOI, the parties intend to establish a 50/50 joint venture to produce low-carbon hydrogen alongside First Atlantic's primary awaruite nickel-cobalt program. The partnership is intended to serve as a first-of-its-kind template for combining hydrogen production with critical mineral development at ultramafic sites, with the potential to attract co-located investment in clean fuels, ammonia, and downstream industry.

"Vema's Engineered Mineral Hydrogen is on the verge of delivering clean energy at a scale cost-competitive with hydrocarbons," said Dr. Douglas Wicks, Strategic Advisor to First Atlantic & Cobalt and former Program Director for ARPA-E's MINER program and Geologic Hydrogen portfolio. "Awaruite forms through serpentinization when hydrogen reduces nickel and iron, so its presence at Pipestone XL is a clear signature of a hydrogen-rich system. Vema's technology could engineer that same reaction for hydrogen production, and Pipestone XL is an ideal location due to its size, proximity to infrastructure, and the potential for cost efficiencies in co-locating hydrogen production with nickel & cobalt mining. Having worked closely with Vema's founders since before the company's founding — and having seen firsthand how they developed the engineered approach to geologic hydrogen — I believe Pipestone XL represents a compelling opportunity to bring this technology to commercial scale."

Over the past twelve months, Vema has worked with First Atlantic to evaluate the Pipestone Ophiolite Complex, analyzing geological and geophysical data as well as infrastructure across the 30-kilometer belt. Laboratory testing of Pipestone rock samples at Vema's Orléans facility in France confirmed hydrogen production through stimulated serpentinization, indicating that the formation is well suited to EMH. Vema will leverage the experience gained in its established site in the Thetford ophiolite in Quebec, where Vema operates the world's first Engineered Mineral Hydrogen project.

Newfoundland is a significant region for critical minerals and clean energy development, but exploration and mining remain energy-intensive. Engineered Mineral Hydrogen (EMH) produces hydrogen from iron-rich rock through naturally occurring geochemical reactions, with no grid electricity required. Locally produced hydrogen at Pipestone could, over time, support on-site energy needs for a large-scale nickel and cobalt mining district and related downstream industries.

"Vema operates the world's first Engineered Mineral Hydrogen project at the Thetford ophiolite in Quebec. Rock samples collected during Vema's site visit to Pipestone XL were tested at their lab in Orléans, France, confirming the hydrogen generation potential of the ultramafic host rocks. Given the link between awaruite formation and hydrogen, we're excited about the potential for Vema's technology to maximize the value of our unique nickel-cobalt alloy project," said Adrian Smith, P.Geo., CEO of First Atlantic.

The collaboration also positions both companies to explore how locally produced hydrogen could reshape energy planning for remote industrial sites. By pairing EMH supply with critical mineral development, the partners aim to demonstrate a model that strengthens regional energy resilience while reducing reliance on long-distance fuel transport.

"Engineered Mineral Hydrogen is a promising new primary energy source for regions with iron-rich rock, like at Pipestone," said Pierre Levin, CEO and Co-Founder of Vema Hydrogen. "Now with validated rock samples and permitting in place, we have a clear path to advance EMH at Pipestone and to expand the model across North America."

Awaruite (Ni₃Fe) is a naturally occurring, magnetic nickel-iron-cobalt alloy (Ni-Fe-Co). The U.S. Geological Survey has identified awaruite as a potential solution to nickel concentrate shortages, noting that it is much easier to concentrate than pentlandite, the principal nickel sulphide. Its magnetic, metallic nature allows recovery by both magnetic separation and flotation, without the smelting, roasting, or acid leaching that conventional nickel ores require.  CONTINUED… Read this and more news for First Atlantic Nickel at:  https://www.fanickel.com/archive

In other market news of interest today includes:

Total Energy Services Inc. (OTC: TOTZF) (TSX:TOT) recently announced its consolidated financial results for the three months ended March 31, 2026.

Total Energy's results for the three months ended March 31, 2026 reflect continued strong North American demand for natural gas compression and process equipment and the deployment of upgraded drilling and service rigs in Australia and Canada that more than offset a year over year decline in North American drilling and completion activity. Negatively impacting first quarter financial results was a $6.5 million year over year increase in share-based compensation expense due to the 52% increase in the Company's share price during the first quarter of 2026. This was partially offset by a $2.9 million year over year increase on the gain on sale of property, plant and equipment following the sale of certain well servicing equipment in the United States in February 2026.

Exxon Mobil Corporation (NYSE: XOM) recently announced its Board of Directors has unanimously recommended shareholders approve changing the company's legal domicile from New Jersey to Texas. The Board concluded that aligning ExxonMobil's legal domicile with where its leadership and core operations have been based since 1989 will benefit shareholders.

"Over the past several years, Texas has made a noticeable effort to embrace the business community. In doing so, it has created a policy and regulatory environment that can allow the company to maximize shareholder value," said Darren Woods, ExxonMobil chairman and chief executive officer. "Aligning our legal home with our operating home, in a state that understands our business and has a stake in the company's success, is important."

In making its recommendation, the Board considered Texas' legal and regulatory environment, including its modernized business statutes and the Texas Business Court, which is designed to resolve complex disputes efficiently. When corporate decisions are challenged, Texas courts are required to apply clear, statute based standards, which support sound decision-making.

Chevron U.S.A. Inc., a subsidiary of Chevron Corporation (NYSE: CVX), recently announced the introduction of next-generation Techron®, a reformulated version of its proprietary gasoline additive designed to provide greater protection for engines from harmful deposits caused by lower quality fuels, supporting long-term engine performance.

Techron has been trusted by drivers for decades as part of Chevron- and Texaco-branded gasolines. The latest reformulation reflects Chevron's continued investment in fuel quality and scientific testing to help ensure its fuels meet the needs of today's engines and driving conditions.

"Fuel technology never stands still," said Andy Walz, president, Chevron Downstream, Midstream and Chemicals. "This new Techron formulation builds on what drivers already expect from our branded fuels – clean engines, reliable performance and confidence at the pump – while reinforcing our continued focus on science based innovation."

Brookfield Renewable Partners L.P. (NYSE: BEP) recently reported financial results for the three months ended March 31, 2026.

"We had a strong start to the year, delivering record financial results, advancing our growth priorities and strengthening our balance sheet. The quarter was highlighted by our acquisition of Boralex, a global, listed renewable platform with a significant operating base and a large, de-risked development pipeline that complements our existing business and where we are uniquely positioned to accelerate growth and create value," said Connor Teskey, CEO of Brookfield Renewable.

He added, "We also continue to increase our development activities, advance key workstreams to support new nuclear deployment at Westinghouse, and scale our capital recycling strategy, agreeing to sell nearly $3 billion of assets this quarter alone. Growing energy demand is now occurring alongside a renewed focus on energy security. In an environment with strong demand for low-cost, quick to market, and increasingly locally sourced energy, we are well positioned to deliver sustainable long-term cash flow growth for our investors."

DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This press release was distributed on behalf of First Atlantic Nickel Corp. For current services performed MNU has been compensated twenty five hundred dollars for news coverage of the current press releases issued by First Atlantic Nickel Corp. by a non-affiliated third party. FNM & MNU HOLD NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information:

Media Contact email: [email protected] - +1(561)486-1799

SOURCE Market News Updates

Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript

Posted by Defense World Staff on Apr 6th, 2026

Capricorn Fund Managers Ltd raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 124.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 445,500 shares of the company’s stock after buying an additional 247,000 shares during the quarter. Roivant Sciences accounts for about 2.3% of Capricorn Fund Managers Ltd’s portfolio, making the stock its 11th largest position. Capricorn Fund Managers Ltd owned approximately 0.06% of Roivant Sciences worth $9,667,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Jones Financial Companies Lllp raised its position in shares of Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after acquiring an additional 1,148 shares during the period. Allworth Financial LP grew its holdings in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the period. Bessemer Group Inc. grew its holdings in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the period. Osaic Holdings Inc. increased its stake in Roivant Sciences by 204.2% in the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock valued at $65,000 after purchasing an additional 3,882 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd increased its stake in Roivant Sciences by 75.8% in the third quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company’s stock valued at $67,000 after purchasing an additional 1,900 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets A number of equities analysts have recently weighed in on the stock. Citigroup lifted their price target on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Sanford C. Bernstein assumed coverage on Roivant Sciences in a research note on Friday, March 20th. They set an “outperform” rating and a $35.00 price objective on the stock. Guggenheim lifted their target price on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Finally, The Goldman Sachs Group increased their price target on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Get Our Latest Report on ROIV

Roivant Sciences Price Performance Roivant Sciences stock opened at $28.33 on Monday. The company has a 50 day moving average of $26.80 and a 200-day moving average of $22.28. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $30.33. The stock has a market capitalization of $20.28 billion, a PE ratio of -24.21 and a beta of 1.20.

Insider Transactions at Roivant Sciences In other news, Director Daniel Allen Gold sold 425,000 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $26.67, for a total value of $11,334,750.00. Following the sale, the director directly owned 15,928,113 shares in the company, valued at $424,802,773.71. The trade was a 2.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Melissa B. Epperly sold 41,861 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the transaction, the director directly owned 15,804 shares of the company’s stock, valued at $453,258.72. This represents a 72.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 4,782,086 shares of company stock worth $128,848,063. Company insiders own 10.80% of the company’s stock.

About Roivant Sciences (Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.

Further Reading Five stocks we like better than Roivant Sciences

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEKarooooo Ltd. $KARO is Capricorn Fund Managers Ltd’s 8th Largest Position

NEXT HEADLINE »Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR

Posted by Defense World Staff on Apr 12th, 2026

Elevate Capital Advisors LLC cut its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 31.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 77,545 shares of the company’s stock after selling 36,236 shares during the quarter. Elevate Capital Advisors LLC’s holdings in Roivant Sciences were worth $1,683,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ROIV. Assenagon Asset Management S.A. grew its holdings in shares of Roivant Sciences by 11,507.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock valued at $150,535,000 after purchasing an additional 6,877,348 shares during the last quarter. Perceptive Advisors LLC bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at approximately $37,546,000. Marshall Wace LLP grew its holdings in shares of Roivant Sciences by 316.5% during the 3rd quarter. Marshall Wace LLP now owns 3,978,001 shares of the company’s stock valued at $60,187,000 after purchasing an additional 3,022,851 shares during the last quarter. Orbimed Advisors LLC bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at approximately $31,324,000. Finally, Rubric Capital Management LP grew its holdings in shares of Roivant Sciences by 14.7% during the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after purchasing an additional 2,603,260 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Analyst Ratings Changes Several equities research analysts recently issued reports on the stock. Citigroup lifted their price target on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a report on Friday, March 20th. They set an “outperform” rating and a $35.00 target price on the stock. Guggenheim boosted their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Leerink Partners boosted their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Finally, Weiss Ratings lowered shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, February 9th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.50.

View Our Latest Stock Report on Roivant Sciences

Insider Activity In other news, insider Frank Torti sold 587,390 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $27.51, for a total value of $16,159,098.90. Following the transaction, the insider owned 13,736,547 shares in the company, valued at approximately $377,892,407.97. The trade was a 4.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Jennifer Humes sold 13,538 shares of the business’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total transaction of $384,073.06. Following the completion of the transaction, the chief accounting officer owned 84,191 shares in the company, valued at $2,388,498.67. This trade represents a 13.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 4,795,624 shares of company stock worth $129,232,136. Company insiders own 10.80% of the company’s stock.

Roivant Sciences Price Performance ROIV opened at $28.21 on Friday. Roivant Sciences Ltd. has a fifty-two week low of $9.57 and a fifty-two week high of $30.33. The firm has a market capitalization of $20.19 billion, a price-to-earnings ratio of -24.11 and a beta of 1.20. The company’s 50 day moving average price is $27.40 and its two-hundred day moving average price is $22.69.

Roivant Sciences Company Profile (Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.

See Also Five stocks we like better than Roivant Sciences

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEElevate Capital Advisors LLC Makes New Investment in Arch Capital Group Ltd. $ACGL

NEXT HEADLINE »Clear Creek Financial Management LLC Purchases 18,300 Shares of Pacer Global Cash Cows Dividend ETF $GCOW

I believe my original bull case on Roivant Sciences has largely played out, with the stock up sharply since my initial coverage. Brepocitinib is clearly now becoming a broader immunology franchise across DM, NIU, CS, and LPP. ROIV also settled with Moderna regarding LNP, which adds to its already cash-rich balance sheet and supports its ongoing buybacks and pipeline.

BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update.

Roivant Sciences Ltd. (ROIV - Free Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.

Therefore, the Zacks rating upgrade for Montes Archimedes Acquisition basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

For Montes Archimedes Acquisition, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for Montes Archimedes AcquisitionFor the fiscal year ending March 2026, this company is expected to earn -$1.07 per share, which is unchanged compared with the year-ago reported number.

Analysts have been steadily raising their estimates for Montes Archimedes Acquisition. Over the past three months, the Zacks Consensus Estimate for the company has increased 27.4%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Montes Archimedes Acquisition to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Roivant Sciences Ltd. (ROIV - Free Report) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -41.18%. A quarter ago, it was expected that this company would post a loss of $0.27 per share when it actually produced a loss of $0.24, delivering a surprise of +11.11%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Montes Archimedes Acquisition, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2.52 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 8.56%. This compares to year-ago revenues of $7.57 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Montes Archimedes Acquisition shares have added about 30% since the beginning of the year versus the S&P 500's gain of 7.4%.

What's Next for Montes Archimedes Acquisition?While Montes Archimedes Acquisition has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Montes Archimedes Acquisition was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.24 on $2 million in revenues for the coming quarter and -$0.58 on $131.57 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 45% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

VistaGen Therapeutics, Inc. (VTGN - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026.

This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of +2.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

VistaGen Therapeutics, Inc.'s revenues are expected to be $0.5 million, up 5100% from the year-ago quarter.

Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Key Takeaways Intellia shares fell 4% despite the phase III data meeting all endpoints for lonvo-z in HAE.NTLA's lonvo-z cut HAE attacks by 87% vs. placebo, with 62% of patients attack-free in the study.Intellia began its rolling BLA submission, targeting completion in H2 2026 and a launch in 2027. Shares of Intellia Therapeutics (NTLA - Free Report) declined 4% on Monday despite positive top-line data from the global phase III HAELO clinical trial evaluating lonvo-z for the treatment of patients with hereditary angioedema (HAE). Lonvo-z is a one-time, outpatient CRISPR-based therapy designed to inactivate the KLKB1 gene, thereby reducing kallikrein and bradykinin levels.

Key Highlights of NTLA’s Phase III HAELO StudyThe phase III randomized, placebo-controlled HAELO study evaluated the safety and efficacy of a one-time 50-milligram dose of lonvo-z in patients aged 16 years and older with type I or type II HAE. Data from the study demonstrated that a one-time infusion of lonvo-z reduced HAE attacks by 87% compared with placebo over the six-month evaluation period. Patients treated with lonvo-z had a much lower average monthly attack rate (0.26) versus 2.10 in the placebo group.

The study met its primary endpoint. It also met all key secondary endpoints with strong statistical significance, including a notably higher proportion of patients who were completely free from both attacks and ongoing therapy (62% versus 11% with placebo). The treatment was well-tolerated, with mild-to-moderate side effects.

Hereditary angioedema (HAE) is a rare genetic disorder marked by recurrent, potentially life-threatening swelling caused by excess bradykinin.

However, it seems that investors were not impressed by the data reported by the company and its stock declined.

Year to date, shares of NTLA have risen 45% against the industry’s 1.2% decline.

Image Source: Zacks Investment Research

NTLA Initiates Rolling Submission of BLA for lonvo-zIn a separate press release, Intellia announced that it has begun a rolling submission of a biologics license application (BLA) to the FDA seeking approval for lonvo-z for the treatment of HAE.

The company expects to complete the BLA submission in the second half of 2026. If accepted, the FDA will determine whether the application qualifies for priority review and will set a target decision date. Intellia plans to commercially launch lonvo-z in the first half of 2027, as the world’s first in vivo CRISPR-based gene editing therapy, if approved.

NTLA’s Zacks Rank & Stocks to ConsiderIntellia Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and Indivior Pharmaceuticals (INDV - Free Report) and ANI Pharmaceuticals (ANIP - Free Report) , which carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.59 to $2.87. Over the same period, EPS estimates for 2027 have surged from $3.01 to $3.25. CPRX shares have gained 25.5% year to date.

Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.

Over the past 90 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.94 to $3.00. Over the same period, EPS estimates for 2027 have surged from $3.22 to $3.29. INDV shares have lost 4.4% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.

Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 earnings per share have increased from $8.22 to $9.02. Over the same period, EPS estimates for 2027 have risen from $9.90 to $10.23. Year to date, shares of ANIP have gained 0.8%.

ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.

April 29, 2026 07:00 ET  | Source: Intellia Therapeutics, Inc.

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the pricing of an underwritten public offering of 16,744,187 shares of its common stock. The shares of common stock are being sold at a public offering price of $10.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $180 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the securities in the offering are to be sold by Intellia. In addition, Intellia has granted the underwriters a 30-day option to purchase up to 2,511,628 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Jefferies, Goldman Sachs & Co. LLC and Citigroup are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The shares of common stock are being offered by Intellia pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-275740) that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 24, 2023 and automatically became effective upon filing. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on April 27, 2026. The final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and may be obtained, when available, from: Jefferies LLC by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected]; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease.

Forward-Looking Statements
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations regarding Intellia’s anticipated public offering; uncertainties related to market conditions and statements regarding the timing, size and expected proceeds of the anticipated offering; the safety, tolerability, efficacy, advancement and success of Intellia’s clinical programs; and Intellia’s ability to successfully execute its business and strategic plans, including the advancement, development and commercialization of its product candidates.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia’s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies’ evaluation of regulatory filings and other information related to our product candidates, including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; the risk that any one or more of Intellia’s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia’s other product candidates; and risks related to Intellia’s reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its quarterly reports on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
[email protected]

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
[email protected]

May 01, 2026 16:01 ET  | Source: Intellia Therapeutics, Inc.

CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on May 1, 2026, it awarded inducement grants to 43 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 208,850 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
[email protected]

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
[email protected]

Tuesday was a rough day for Shopify (SHOP +2.06%), Intellia Therapeutics (NTLA +1.23%), and GeneDX Holdings (WGS +12.28%) investors. All three growth stocks tumbled between 4% and 49%. As the market was selling off those once high-flying stocks, Cathie Wood was buying.

Wood's Ark Invest added to all three existing positions on Tuesday. They were the only three stocks Ark Invest bought during the trading day. Let's take a closer look at what could be drawing the founder and CEO of Ark Invest to buy into Shopify, Intellia Therapuetics, and GeneDX on the way down.

Image source: Getty Images.

1. Shopify Let's start with the good news. Shopify stock is nearly a 50-bagger since its IPO. It's even trading higher over the past year. However, the online marketplace operator is falling again after a poorly received financial update in which soft guidance ruined an otherwise solid performance.

Revenue rose 34% for the first quarter, fueled by a 35% jump in gross merchandise volume for the merchants leaning on Shopify's e-commerce solutions. Adjusted net income fared even better, surging 44%. Both ends of the income statement exceeded expectations, but a recurring theme this earnings season has been strong quarters tripped up by a cautionary near-term tone.

Today's Change

(

2.06

%) $

2.23

Current Price

$

110.43

Now for the bad news. Shopify expects year-over-year revenue growth to decelerate in the current quarter. It's targeting an increase in the high twenties on a percentage basis. This is pretty much where Wall Street pros were anyway, but it dulls the excitement over the first quarter's 34% top-line jump.

It also doesn't help that Shopify isn't exactly cheap. Even after Tuesday's 16% slide, the stock is still trading for more than 50 times forward earnings. Thankfully, a high P/E ratio hasn't stopped Shopify before. It's still generating gobs of free cash flow, and its guidance for the new quarter should extend its streak of a double-digit free cash flow margin to 12 consecutive quarters.

This high-beta stock will remain volatile. Wood doesn't have a problem with that. She's buying as others are selling, and betting against Shopify hasn't been a winning trade for investors with long-term horizons.

Today's Change

(

1.23

%) $

0.15

Current Price

$

12.35

2. Intellia Therapeutics Unlike the double-digit percentage hits for the other two stocks on Wood's shopping list on Tuesday, Intellia was limited to a 4% retreat. One of Wood's most popular gene-editing stocks, the developer of next-gen treatments based on CRISPR therapies is connecting with analysts.

Whitney Ijem at Canaccord boosted his firm's price target from $48 to $58 last week, encouraged by recent positive data from a phase 3 clinical trial of a promising treatment. He's not even the Street-high on the shares. One analyst thinks Intellia is headed to $95, a big deal for a stock trading in the low teens.

Today's Change

(

12.28

%) $

6.67

Current Price

$

60.99

3. GeneDX Holdings One of Tuesday's biggest losers was GeneDX. Shares of the genomics company specializing in the diagnosis of rare diseases shed nearly half of their value after posting disappointing first-quarter results. A report has to be pretty bad for a stock to plunge 49% in a single trading day, so let's take a closer look.

Revenue rose 17% to $102.3 million through the first three months of this year. After seeing revenue soar 51% and then 40% in the past two years, analysts were holding out for a nearly 30% increase on the top line for the quarter. GeneDX's bread-and-butter exome and genome revenue rose a respectable 27%, but shortfalls elsewhere -- including its average reimbursement rates -- dragged overall results down. It also fell short of expectations on the bottom line.

This wasn't just a one-time fluke. GeneDX is resetting expectations. It now sees $475 million to $490 million in revenue for all of 2026, down from the $540 million to $555 million it was targeting earlier this year. After coming up short by $10 million on the top line in the first quarter, it's slashing the midpoint of its full-year outlook by $65 million. This appears to be a situation that will get worse instead of better in the near term.

Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U. S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z in ATTR-CM and ATTRv-PN, respectively Including proceeds from underwritten public offering in April, existing cash resources expected to fund operations at least into 2028 CAMBRIDGE, Mass.

Key Takeaways NTLA posted a narrower Q1 loss as research and development costs fell, though revenues declined 9.5% y/y.NTLA resumed phase III nex-z studies after the FDA lifted clinical holds in ATTR-CM and ATTRv-PN.Intellia began a rolling FDA filing for lonvo-z after phase III data showed 87% fewer HAE attacks. Intellia Therapeutics (NTLA - Free Report) incurred first-quarter 2026 loss of 81 cents per share, narrower than the Zacks Consensus Estimate of a loss of 92 cents. In the year-ago quarter, the company had incurred a loss of $1.10 per share.

Intellia’s total revenues currently comprise only collaboration revenues. The company reported revenues of $15 million for the first quarter of 2026, which missed the Zacks Consensus Estimate of $16 million. Total revenues declined 9.5% year over year.

Year to date, shares of NTLA have surged 60.4% against the industry’s 2.7% decline.

Image Source: Zacks Investment Research

NTLA’s Q1 Results in DetailResearch and development expenses totaled $80.7 million, down 25.5% from the year-ago quarter’s figure. The decrease was due to lower employee-related expenses, stock-based compensation and reduced spending on research materials and contracted services.

General and administrative expenses in the first quarter were $34.8 million, up 20.1% year over year, primarily due to continued investments in building the company’s commercial infrastructure and higher legal expenses, partially offset by lower stock-based compensation.

As of March 31, 2026, Intellia had cash, cash equivalents and marketable securities worth $517.2 million compared with $605.1 million as of Dec. 31, 2025.

Following an underwritten public offering of common stock, the company expects its cash runway to support operations into 2028.

NTLA's Recent Pipeline UpdatesIntellia has collaborated with Regeneron Pharmaceuticals (REGN - Free Report) to develop its investigational in vivo genome-editing candidate, nexiguran ziclumeran (nex-z), which is being studied for two indications — ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM).

In March, the FDA lifted the clinical hold on the investigational new drug application (IND) for the phase III MAGNITUDE study evaluating nex-z in patients with ATTR-CM.

Earlier this year, the FDA lifted the clinical hold on the IND application for the phase III study, MAGNITUDE-2, evaluating nex-z in patients with ATTRv-PN. Enrollment in this study is expected to be completed in the second half of 2026.

With the removal of the clinical hold, Intellia is now focusing on completing patient enrollment in both late-stage studies as promptly as possible.

In April, Intellia announced top-line data from the global phase III HAELO study evaluating lonvo-z, an in vivo CRISPR gene editing therapy, for the treatment of hereditary angioedema (HAE). The study met its primary endpoint and all key secondary endpoints.

The study demonstrated that a one-time infusion of lonvo-z reduced HAE attacks by 87% compared with placebo over the six-month evaluation period. Patients treated with lonvo-z had a much lower average monthly attack rate (0.26) versus 2.10 in the placebo group. Per data, the company initiated a rolling submission of a biologics license application (BLA) to the FDA seeking approval for lonvo-z for the treatment of HAE.

The company expects to complete the BLA submission in the second half of 2026. Intellia plans to commercially launch lonvo-z in the first half of 2027, as the world’s first in vivo CRISPR-based gene editing therapy, if approved.

NTLA’s Zacks Rank & Stocks to ConsiderIntellia currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Amarin Corporation (AMRN - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , both currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $7.01 to $6.36. Over the same period, loss per share estimates for 2027 have also narrowed from $5.50 to $4.64. AMRN shares have risen 7.6% year to date.

Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 50.02%.

Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.03 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.46. INDV shares have risen 8.2% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

Key Takeaways Intellia advanced phase III studies for nex-z in ATTR amyloidosis after the FDA lifted clinical holds.NTLA said the phase III HAELO study for lonvo-z met primary and key secondary endpoints.Intellia plans a 2027 launch for lonvo-z, pending FDA approval after completing BLA submission. Intellia Therapeutics (NTLA - Free Report) has been making decent progress with the advancement of its two pipeline candidates, nex-z (or, NTLA-2001) for transthyretin (ATTR) amyloidosis and lonvo-z (or NTLA-2002) for hereditary angioedema (HAE).

Intellia is developing nex-z in collaboration with Regeneron Pharmaceuticals (REGN - Free Report) . The candidate is being evaluated in two late-stage studies, MAGNITUDE and MAGNITUDE-2, for ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTR amyloidosis with polyneuropathy (ATTRv-PN), respectively.

While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits. The company’s top line currently comprises only collaboration revenues from its partners, like Regeneron and others.

In March, the FDA lifted the clinical hold on the investigational new drug (IND) application for the phase III MAGNITUDE study evaluating nex-z in patients with ATTR-CM.

Earlier this year, the FDA lifted the clinical hold on the IND application for the phase III study, MAGNITUDE-2, evaluating nex-z in patients with ATTRv-PN. Enrollment in this study is expected to be completed in the second half of 2026.

Intellia is now focusing on completing patient enrollment in both late-stage studies as promptly as possible. The successful development of nex-z could provide impetus to the stock and create long-term growth visibility.

Meanwhile, last month, Intellia announced that the phase III HAELO study evaluating lonvo-z, an in vivo CRISPR gene editing therapy, for the treatment of HAE, has met its primary endpoint and all key secondary endpoints.

Simultaneously, NTLA initiated a rolling submission of a biologics license application (BLA) to the FDA seeking approval for lonvo-z for the treatment of HAE. The company expects to complete the BLA submission in the second half of 2026. Intellia plans to commercially launch lonvo-z in the first half of 2027, upon potential approval.

The successful development of its pipeline candidates will be a huge boost to Intellia. However, any regulatory or developmental setback related to ongoing studies will be a major setback. Growing competition in the target market also remains a worry.

NTLA's Competition in the Target MarketWhile Intellia’s pipeline of innovative CRISPR-based therapies appears promising, developing these candidates remains a complex and challenging process. Even if successfully developed and approved, the therapies are likely to face competition from other companies leveraging CRISPR/Cas9 gene-editing technology to target diseases across similar therapeutic areas.

CRISPR Therapeutics (CRSP - Free Report) is the first and only company in the world to market a CRISPR/Cas9-based therapy. CRSP’s one-shot gene therapy, Casgevy, was approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications — sickle cell disease and transfusion-dependent beta-thalassemia.

CRSP has developed Casgevy in partnership with large biotech, Vertex Pharmaceuticals, which is responsible for the therapy’s global development and commercialization.

Beam Therapeutics (BEAM - Free Report) is developing its leading ex-vivo genome-editing candidate, risto-cel, in the phase I/II BEACON study for the treatment of patients with SCD. BEAM plans to submit a BLA for risto-cel by the end of 2026.

Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for the treatment of glycogen storage disease type 1a and alpha-1 antitrypsin deficiency, respectively.

NTLA's Price Performance, Valuation and EstimatesYear to date, shares of Intellia have rallied 41.1% against the industry’s decline of 2.2%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.

Image Source: Zacks Investment Research

From a valuation standpoint, Intellia is trading at a discount to the industry. Going by the price/book ratio, the company’s shares currently trade at 2.46, lower than 3.13 for the industry. The stock is trading below its five-year mean of 2.58.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Intellia’s 2026 loss per share has narrowed from $3.53 to $3.35 over the past 30 days. Loss per share estimates for 2027 have widened from $1.22 to $1.54 during the same time frame.

Image Source: Zacks Investment Research

NTLA's Zacks RankIntellia currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Intellia Therapeutics remains a Buy, driven by two pivotal in vivo gene therapy catalysts: Lonvo-Z for HAE and Nex-Z for ATTR amyloidosis. Lonvo-Z's Phase 3 data met all endpoints with an 87% attack reduction, but market reaction was muted due to safety concerns and the competitive landscape. The FDA lifted clinical holds on Nex-Z Phase 3 trials, enabling advancement in a $16.8bn ATTR market with a differentiated one-time treatment profile.

June 05, 2026 16:05 ET  | Source: Intellia Therapeutics, Inc.

CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 47,150 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
[email protected]

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
[email protected]

Brian Busse, General Counsel of Arlo Technologies (ARLO +3.17%), reported the sale of 25,525 direct shares for approximately $352K following the addition of shares on March 12, 2026, according to a SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)25,525Transaction value~$352KPost-transaction shares (direct)583,364Post-transaction value (direct ownership)~$7.88 millionTransaction value based on SEC Form 4 weighted average purchase price ($13.78); post-transaction value based on March 12, 2026 market close ($13.78).

Key questionsWhat is the context of this trade?
The sale of 25,525 shares followed Busse’s addition of 50,000 shares under a performance stock unit (PSU) plan. The sale of shares was only conducted to satisfy estimated tax withholding obligations. How significant is the reduction in ownership as a result of this sale?
The transaction reduced Busse's direct holdings by 4.19%, leaving him with 583,364 shares valued at approximately ~$7.88 million as of the transaction date. Company overviewMetricValueMarket capitalization$1.53 billionRevenue (TTM)$529.30 millionNet income (TTM)$14.93 million1-year price change (as of 3/21/26)32%

Today's Change

(

3.17

%) $

0.39

Current Price

$

12.71

Company snapshotArlo Technologies is a cloud-based platform that offers a portfolio of smart, connected security devices, including indoor and outdoor cameras, video doorbells, floodlight cameras, and accessories, all integrated with a proprietary cloud platform and mobile applications. Along with product sales, it has a subscription-based service model that drives recurring revenue and customer engagement. It targets residential and small-business customers seeking intelligent, cloud-enabled security and monitoring solutions across the Americas, Europe, the Middle East, Africa, and Asia.

What this transaction means for investorsIt’s important to emphasize that this sale was strictly to cover estimated taxes for the 50,000 PSUs that vested into shares on March 10, through Busse’s PSU plan with the company. And while having to sell over half the shares he gained for taxes, the general counsel member technically gained more shares than he lost when looking at the entire filing.

Arlo Technologies is less than a month removed from a very strong Q4 earnings report for its fiscal year of 2025. On Feb. 26, 2026, the company reported its first fiscal year of net income, after years of annual net losses. It also posted its largest year-over-year (YoY) increase in quarterly free cash flow since Q2 2021, with its 17.94 million in free cash flow being 220.59% higher than the previous year’s Q4.

The stock jumped in February 2026 after the strong postings, and it is up 2.57% so far this year. Early in March, the company announced a $50 million stock repurchase program, approved by its Board of Directors and set to continue through Dec. 31, 2027. This may help drive share prices even higher.

With strong financials and stock performance, Arlo Technologies looks like a considerable investment opportunity in the smart home security industry.

Posted by Defense World Staff on Mar 30th, 2026

Shares of Arlo Technologies, Inc. (NYSE:ARLO – Get Free Report) have received an average rating of “Moderate Buy” from the five research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $23.3333.

ARLO has been the topic of a number of research reports. Weiss Ratings upgraded Arlo Technologies from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, March 6th. Zacks Research downgraded shares of Arlo Technologies from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th.

View Our Latest Research Report on Arlo Technologies

Arlo Technologies Stock Up 0.3% ARLO opened at $13.50 on Friday. The firm has a market capitalization of $1.44 billion, a P/E ratio of 103.84 and a beta of 1.65. The stock has a fifty day moving average of $13.24 and a 200-day moving average of $14.85. Arlo Technologies has a 12-month low of $7.84 and a 12-month high of $19.94.

Arlo Technologies (NYSE:ARLO – Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.06. The firm had revenue of $141.30 million for the quarter, compared to analyst estimates of $135.57 million. Arlo Technologies had a return on equity of 10.76% and a net margin of 2.82%.Arlo Technologies’s quarterly revenue was up 16.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 earnings per share. Arlo Technologies has set its Q1 2026 guidance at 0.170-0.230 EPS. On average, analysts expect that Arlo Technologies will post -0.29 earnings per share for the current fiscal year.

Arlo Technologies announced that its board has initiated a share repurchase program on Wednesday, March 4th that authorizes the company to repurchase $50.00 million in shares. This repurchase authorization authorizes the company to buy up to 3.1% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

Insider Activity In other news, General Counsel Brian Busse sold 31,407 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $12.29, for a total transaction of $385,992.03. Following the transaction, the general counsel directly owned 552,850 shares in the company, valued at $6,794,526.50. The trade was a 5.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Matthew Blake Mcrae sold 153,433 shares of the company’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $13.78, for a total transaction of $2,114,306.74. Following the completion of the transaction, the chief executive officer directly owned 1,168,866 shares in the company, valued at $16,106,973.48. This trade represents a 11.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 842,522 shares of company stock worth $11,321,821 in the last ninety days. Corporate insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Arlo Technologies A number of hedge funds and other institutional investors have recently made changes to their positions in ARLO. AQR Capital Management LLC grew its stake in shares of Arlo Technologies by 28.8% in the 1st quarter. AQR Capital Management LLC now owns 406,688 shares of the company’s stock valued at $4,014,000 after buying an additional 90,970 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Arlo Technologies by 15.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 171,986 shares of the company’s stock valued at $1,698,000 after acquiring an additional 23,068 shares during the last quarter. Millennium Management LLC lifted its stake in Arlo Technologies by 116.1% in the first quarter. Millennium Management LLC now owns 455,692 shares of the company’s stock valued at $4,498,000 after acquiring an additional 244,783 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Arlo Technologies by 115.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,552,652 shares of the company’s stock worth $15,325,000 after acquiring an additional 830,770 shares in the last quarter. Finally, Jane Street Group LLC increased its stake in shares of Arlo Technologies by 279.8% during the 1st quarter. Jane Street Group LLC now owns 292,302 shares of the company’s stock worth $2,885,000 after purchasing an additional 215,343 shares during the last quarter. 83.18% of the stock is owned by hedge funds and other institutional investors.

Arlo Technologies Company Profile (Get Free Report)

Arlo Technologies, Inc (NYSE: ARLO) is a provider of smart home security products and services designed for residential and small business customers. The company offers a portfolio of wireless and Wi-Fi-enabled security cameras, video doorbells, smart lighting solutions, and associated accessories. Arlo integrates advanced video analytics, motion detection, cloud storage, and two-way audio capabilities to deliver end-to-end security and monitoring solutions accessible through mobile applications and web interfaces.

Founded as a division of Netgear, Inc in 2014 and spun off as an independent public company in 2018, Arlo Technologies has established a presence in North America, Europe, Australia and parts of Asia.

Featured Stories Five stocks we like better than Arlo Technologies

Receive News & Ratings for Arlo Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arlo Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEMidland States Bancorp, Inc. (NASDAQ:MSBI) Receives $23.00 Average PT from Analysts

NEXT HEADLINE »Galp Energia SGPS SA (OTCMKTS:GLPEY) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Posted by Defense World Staff on Apr 9th, 2026

Arlo Technologies, Inc. (NYSE:ARLO – Get Free Report) CFO Kurtis Joseph Binder sold 25,000 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $13.99, for a total value of $349,750.00. Following the sale, the chief financial officer directly owned 589,885 shares in the company, valued at $8,252,491.15. This trade represents a 4.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kurtis Joseph Binder also recently made the following trade(s):

On Thursday, March 12th, Kurtis Joseph Binder sold 179,419 shares of Arlo Technologies stock. The stock was sold at an average price of $13.78, for a total value of $2,472,393.82. On Wednesday, March 4th, Kurtis Joseph Binder sold 9,665 shares of Arlo Technologies stock. The stock was sold at an average price of $15.11, for a total value of $146,038.15. On Tuesday, March 3rd, Kurtis Joseph Binder sold 12,539 shares of Arlo Technologies stock. The stock was sold at an average price of $14.93, for a total value of $187,207.27. On Friday, January 9th, Kurtis Joseph Binder sold 55,043 shares of Arlo Technologies stock. The stock was sold at an average price of $13.69, for a total value of $753,538.67. Arlo Technologies Stock Performance Shares of NYSE ARLO opened at $13.60 on Thursday. Arlo Technologies, Inc. has a fifty-two week low of $8.37 and a fifty-two week high of $19.94. The firm has a market capitalization of $1.45 billion, a PE ratio of 104.62 and a beta of 1.71. The stock’s 50-day simple moving average is $13.32 and its 200-day simple moving average is $14.66.

Arlo Technologies (NYSE:ARLO – Get Free Report) last issued its earnings results on Friday, February 27th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.06. The business had revenue of $141.30 million for the quarter, compared to analyst estimates of $135.57 million. Arlo Technologies had a return on equity of 10.76% and a net margin of 2.82%.The business’s quarterly revenue was up 16.2% on a year-over-year basis. During the same quarter last year, the company earned $0.10 EPS. On average, sell-side analysts forecast that Arlo Technologies, Inc. will post -0.29 earnings per share for the current fiscal year.

Arlo Technologies declared that its board has initiated a share repurchase program on Wednesday, March 4th that permits the company to buyback $50.00 million in outstanding shares. This buyback authorization permits the company to buy up to 3.1% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Institutional Inflows and Outflows Several hedge funds and other institutional investors have recently modified their holdings of the stock. Arizona State Retirement System grew its stake in shares of Arlo Technologies by 2.3% in the 3rd quarter. Arizona State Retirement System now owns 30,597 shares of the company’s stock valued at $519,000 after purchasing an additional 702 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Arlo Technologies by 86.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,616 shares of the company’s stock valued at $28,000 after purchasing an additional 747 shares during the last quarter. Quarry LP grew its stake in shares of Arlo Technologies by 42.0% in the 3rd quarter. Quarry LP now owns 2,649 shares of the company’s stock valued at $45,000 after purchasing an additional 783 shares during the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of Arlo Technologies by 3.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 24,268 shares of the company’s stock valued at $340,000 after purchasing an additional 800 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its stake in shares of Arlo Technologies by 12.5% in the 4th quarter. Farther Finance Advisors LLC now owns 7,631 shares of the company’s stock valued at $107,000 after purchasing an additional 849 shares during the last quarter. 83.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes A number of research analysts recently issued reports on ARLO shares. Zacks Research downgraded Arlo Technologies from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Weiss Ratings upgraded Arlo Technologies from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, March 6th. Three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Arlo Technologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.33.

Get Our Latest Research Report on ARLO

Arlo Technologies Company Profile (Get Free Report)

Arlo Technologies, Inc (NYSE: ARLO) is a provider of smart home security products and services designed for residential and small business customers. The company offers a portfolio of wireless and Wi-Fi-enabled security cameras, video doorbells, smart lighting solutions, and associated accessories. Arlo integrates advanced video analytics, motion detection, cloud storage, and two-way audio capabilities to deliver end-to-end security and monitoring solutions accessible through mobile applications and web interfaces.

Founded as a division of Netgear, Inc in 2014 and spun off as an independent public company in 2018, Arlo Technologies has established a presence in North America, Europe, Australia and parts of Asia.

Featured Articles Five stocks we like better than Arlo Technologies

Receive News & Ratings for Arlo Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arlo Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEFlagship Harbor Advisors LLC Decreases Stock Position in Waste Management, Inc. $WM

NEXT HEADLINE »Siraj Nour El-Ahmadi Sells 54,536 Shares of Lightwave Logic (NASDAQ:LWLG) Stock